WallStreetZen

NYSE: CRL
Charles River Laboratories International Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CRL

Based on 9 analysts offering 12 month price targets for Charles River Laboratories International Inc.
Min Forecast
$334.00-24.05%
Avg Forecast
$373.33-15.11%
Max Forecast
$465.00+5.73%

Should I buy or sell CRL stock?

Based on 10 analysts offering ratings for Charles River Laboratories International Inc.
Buy
Strong Buy
6 analysts 60%
Buy
0 analysts 0%
Hold
4 analysts 40%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

CRL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
UBS
Top 31%
70
Strong BuyMaintains$465.00+5.73%2021-08-17
Credit Suisse
Top 27%
74
HoldMaintains$385.00-12.46%2021-07-20
Citigroup
Top 3%
98
HoldMaintains$355.00-19.28%2021-05-28
Credit Suisse
Top 3%
98
HoldMaintains$352.00-19.96%2021-05-28
JP Morgan
Top 16%
85
Strong BuyMaintains$390.00-11.32%2021-05-28
Truist Securities
Top 3%
98
Strong BuyMaintains$369.00-16.10%2021-05-25
KeyBanc
Top 7%
94
Strong BuyMaintains$360.00-18.14%2021-05-14
Morgan Stanley
Top 3%
98
Strong BuyMaintains$350.00-20.42%2021-02-22
Deutsche Bank
Top 16%
85
Strong BuyMaintains$334.00-24.05%2021-02-18
Anonymous
Citigroup
HoldDowngradesN/AN/A2020-12-16

1 of 1

Forecast return on equity

Is CRL forecast to generate an efficient return?
Company
32.89%
Industry
47.45%
Market
30.41%
CRL's Return on Equity is forecast to be high in 3 years (32.89%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is CRL forecast to generate an efficient return on assets?
Company
11.35%
Industry
15.94%
Market
15.13%
CRL is forecast to generate lower Return on Assets (11.35%) than the US Diagnostics & Research industry average (15.94%)
Forecast

CRL earnings per share forecast

What is CRL's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$10.25+29.09%
Avg 2 year Forecast
$11.72+47.55%
Avg 3 year Forecast
$13.46+69.55%
CRL's earnings are forecast to grow at a rate of 19.03% per year, which is not exceptional
Forecast

CRL revenue forecast

What is CRL's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$3.6B+8.84%
Avg 2 year Forecast
$3.9B+20.31%
Avg 3 year Forecast
$4.3B+32.21%
CRL's revenue is forecast to grow at a rate of 9.73% per year, which is not exceptional
Forecast

CRL earnings growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
19.03%
Industry
16.52%
Market
18.84%
CRL's earnings are forecast to grow faster (19.03% per year) than the US Diagnostics & Research industry average (16.52%)
Forecast
CRL's earnings are forecast to grow faster (19.03% per year) than the US market average (18.84%)
Forecast
CRL's earnings are forecast to grow faster (19.03% per year) than the risk-free savings rate (1.3%)
Forecast

CRL revenue growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
9.73%
Industry
11.12%
Market
12.2%
CRL's revenues are forecast to grow slower (9.73% per year) than the US Diagnostics & Research industry average (11.12%)
Forecast
CRL's revenues are forecast to grow slower (9.73% per year) than the US market average (12.2%)
Forecast

Charles River Laboratories International Stock Forecast FAQ

Is Charles River Laboratories International Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 10 Wall Street analysts covering (NYSE: CRL) stock is to Buy CRL stock.

Out of 10 analysts, 6 (60%) are recommending CRL as a Strong Buy, 0 (0%) are recommending CRL as a Buy, 4 (40%) are recommending CRL as a Hold, 0 (0%) are recommending CRL as a Sell, and 0 (0%) are recommending CRL as a Strong Sell.

What is CRL's earnings growth forecast for 2021-2023?

(NYSE: CRL) Charles River Laboratories International's forecast annual earnings growth rate of 19.03% is forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 16.52%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 18.84%.

Charles River Laboratories International's earnings in 2021 is $396,078,000.On average, 7 Wall Street analysts forecast CRL's earnings for 2021 to be $516,565,376, with the lowest CRL earnings forecast at $497,918,625, and the highest CRL earnings forecast at $526,644,700. On average, 7 Wall Street analysts forecast CRL's earnings for 2022 to be $590,431,704, with the lowest CRL earnings forecast at $583,592,883, and the highest CRL earnings forecast at $597,199,971.

In 2023, CRL is forecast to generate $678,464,524 in earnings, with the lowest earnings forecast at $668,763,174 and the highest earnings forecast at $688,417,857.

What is CRL's revenue growth forecast for 2021-2023?

(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 9.73% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 11.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.2%.

Charles River Laboratories International's revenue in 2021 is $3,273,463,000.On average, 5 Wall Street analysts forecast CRL's revenue for 2021 to be $179,559,636,422, with the lowest CRL revenue forecast at $178,290,649,481, and the highest CRL revenue forecast at $180,334,232,503. On average, 6 Wall Street analysts forecast CRL's revenue for 2022 to be $198,481,098,549, with the lowest CRL revenue forecast at $188,957,094,527, and the highest CRL revenue forecast at $202,596,940,271.

In 2023, CRL is forecast to generate $218,102,519,358 in revenue, with the lowest revenue forecast at $207,525,729,903 and the highest revenue forecast at $226,118,253,277.

What is CRL's forecast return on assets (ROA) for 2021-2024?

(NYSE: CRL) forecast ROA is 11.35%, which is lower than the forecast US Diagnostics & Research industry average of 15.94%.

What is CRL's Price Target?

According to 9 Wall Street analysts that have issued a 1 year CRL price target, the average CRL price target is $373.33, with the highest CRL stock price forecast at $465.00 and the lowest CRL stock price forecast at $334.00.

On average, Wall Street analysts predict that Charles River Laboratories International's share price could stay at $373.33 by Aug 17, 2022. The average Charles River Laboratories International stock price prediction forecasts a potential downside of N/A from the current CRL share price of $439.79.

What is CRL's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: CRL) Charles River Laboratories International's current Earnings Per Share (EPS) is $7.94. On average, analysts forecast that CRL's EPS will be $10.25 for 2021, with the lowest EPS forecast at $9.88, and the highest EPS forecast at $10.45. On average, analysts forecast that CRL's EPS will be $11.72 for 2022, with the lowest EPS forecast at $11.58, and the highest EPS forecast at $11.85. In 2023, CRL's EPS is forecast to hit $13.46 (min: $13.27, max: $13.66).

What is CRL's forecast return on equity (ROE) for 2021-2024?

(NYSE: CRL) forecast ROE is 32.89%, which is considered strong.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.